Tag
Immunotherapy use in older patients with advanced endometrial cancer has increased over recent years but remains lower among the oldest and racial minorities, highlighting persisting treatment disparities.
This review synthesizes recent evidence demonstrating persistent racial and ethnic disparities in treatment initiation and survival among patients with advanced endometrial cancer, highlighting the critical influence of socioeconomic status
In a large, diverse cohort of women with endometrial cancer, 11.9% harbored pathogenic germline variants, including Lynch syndrome and homologous recombination deficiency-related mutations. Testing at diagnosis identified most Lynch syndrom
This study reveals that lower serum GLP-1 levels are independently associated with endometrial cancer in obese, non-diabetic women, suggesting its potential as a diagnostic biomarker with high sensitivity and specificity.
This study reveals significant discordance between HER2 scores from endometrial biopsy samples and hysterectomy specimens using gastric scoring criteria, impacting treatment decisions in high-grade endometrial cancer.
This study reveals distinct alterations in the type I interferon pathway expression and signaling linked to mutated p53 subtypes in endometrial cancer, highlighting differing immune microenvironments that impact prognosis and therapeutic co
Over 25% of endometrial cancer patients receiving chemotherapy develop venous thromboembolism, with advanced cancer stage as the key risk factor, highlighting the need for tailored risk assessment and preventive strategies.
Sentinel lymph node biopsy in atypical endometrial hyperplasia patients identifies occult cancers and refines adjuvant treatment strategies, supporting its safe and feasible use for better risk stratification.
This article analyzes 40-year trends in incidence, mortality, and survival of endometrial, ovarian, and cervical cancers among Nordic women aged 0-49, highlighting evolving epidemiology and implications for age-specific prevention.
A clear, evidence-based summary of the 2026 SGO–SAGES clinical practice statement recommending integration of metabolic and bariatric surgery into multidisciplinary care for women with EIN and endometrial cancer.
This study analyzes real-world data showing that MLH1 promoter hypermethylation and Lynch syndrome-associated genetic mutations confer similar response rates and survival outcomes in mismatch repair deficient endometrial cancer treated with
A large retrospective study demonstrates that adding SGLT2 inhibitors to progestin therapy in women with benign uterine diseases reduces the risk of developing endometrial cancer and the need for hysterectomy.
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
TCGA-based transcriptome analysis suggests high CCNA2 and E2F1 expression marks poor progression-free survival and probable platinum insensitivity in endometrial cancer, supporting pretreatment molecular stratification and alternative thera
This review synthesizes findings from a large-scale cohort study comparing laparoscopic and abdominal hysterectomy, highlighting significant surgical advantages for laparoscopy despite complex survival data.
A new study reveals that selective molecular profiling with MMR/p53 IHC followed by NGS for p53-abnormal tumors is more cost-efficient than universal NGS for advanced endometrial cancer, reducing unnecessary testing by 57%.
Researchers successfully reduced a 19-marker DNA panel to just 2 methylated DNA markers that detect endometrial cancer with 96% sensitivity and 82% specificity using self-collected vaginal fluid, offering a less invasive alternative to endo
A real-world study of 671 endometrial cancer patients reveals significant molecular heterogeneity. PTEN, ARID1A, and PIK3CA are the most prevalent biomarkers, while TP53 mutations and ERBB2 amplification cluster in advanced-stage and non-en
This retrospective study challenges the assumption that prior radiation limits immunotherapy effectiveness in recurrent endometrial and cervical cancers, finding no significant difference in response rates or survival outcomes based on recu
This review analyzes community-validated strategies to improve biobanking engagement among Black women with endometrial cancer, highlighting return-of-value, transparency, and trust-building as essential components for reducing health dispa
